• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Why 4DMedical (ASX:4DX) Is Up 28.4% After Expanded Philips CT:VQ Distribution Deal - And What's Next

    Simply Wall St·12/16/2025 00:27:52
    語音播報
    • In early December 2025, Koninklijke Philips held a special call announcing a significant expansion of its distribution agreement for 4DMedical’s FDA-cleared, non-contrast CT:VQ ventilation and perfusion imaging solution.
    • This move could materially widen commercial access to CT:VQ by leveraging Philips’ global imaging footprint, potentially accelerating hospital adoption of 4DMedical’s technology.
    • We’ll now examine how the expanded Philips distribution for CT:VQ may influence 4DMedical’s investment narrative and future growth assumptions.

    Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 36 best rare earth metal stocks of the very few that mine this essential strategic resource.

    4DMedical Investment Narrative Recap

    To own 4DMedical, you need to believe its lung imaging software can scale fast enough to justify ongoing losses and dilution risk. The Philips CT:VQ distribution expansion directly reinforces the core near term catalyst of commercial uptake, but it does not remove the key cash runway and funding overhang that still sit in the foreground for shareholders.

    The most relevant recent development to view alongside the Philips news is the September 2025 FDA 510(k) clearance and CMS reimbursement for CT:VQ, which formally opened the door to US clinical use and payment. Philips’ broader distribution now plugs into that regulatory and reimbursement foundation, so the pace at which hospitals convert interest into billable scans remains central to whether the growth thesis can keep up with the company’s funding needs.

    Yet against the excitement around Philips, investors should be aware that the short cash runway still...

    Read the full narrative on 4DMedical (it's free!)

    4DMedical's narrative projects A$48.5 million revenue and A$17.4 million earnings by 2028. This requires 102.3% yearly revenue growth and an A$56.9 million earnings increase from A$-39.5 million today.

    Uncover how 4DMedical's forecasts yield a A$2.30 fair value, a 6% downside to its current price.

    Exploring Other Perspectives

    ASX:4DX 1-Year Stock Price Chart
    ASX:4DX 1-Year Stock Price Chart

    Simply Wall St Community members have published 10 fair value estimates for 4DMedical, ranging from A$0.19 to A$4.25 per share, showing how far apart individual views can be. When you set those expectations against the company’s limited cash runway and reliance on future capital raises, it underlines why checking several perspectives before forming your own view on 4DMedical’s prospects can be useful.

    Explore 10 other fair value estimates on 4DMedical - why the stock might be worth as much as 74% more than the current price!

    Build Your Own 4DMedical Narrative

    Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

    Ready To Venture Into Other Investment Styles?

    The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.